Cancer is a condition that results in the uncontrolled growth of cells. It is quite difficult to control this condition. A wide range of medications is administered to a patient suffering from this condition. Bevacizumab is one such medication. It is also popular by its trade name Avastin. Bevacizumab is beneficial in the treatment of different kinds of cancer. It has also been found to be effective in treating certain age-related eye conditions such as macular degeneration. The wholesale cost of this drug is about £495 per vial in the developing world. Bevacizumab belongs to the monoclonal antibody class of medication. It functions by slowing down the growth of new blood vessels. This drug was approved for medical use in 2004. It has been listed by the WHO as one of the most effective and safest medicines needed for a health system. It features in the list of the role it plays in treating eye conditions. The wholesale cost of this drug in the developing world is about £495 per vial. The dose cost the NHS about £242.66 in the United Kingdom in 2015.

Bevacizumab was approved for use in treating metastatic colorectal cancer in 2004. It was used along with standard chemotherapy treatment. It was approved by the European Medicines Agency (EMA) in 2005. Bevacizumab was approved as a first-line treatment for non-small cell lung cancer along with paclitaxel chemotherapy. The approval was based on a pivotal study done which demonstrated improvement in overall survival when treated with this drug. This drug is primarily given intravenously once every 14 days. For colon cancer, it is given in combination with the chemotherapy drug. It is injected intravitreally for treating eye diseases.

Bevacizumab is one of the pharmaceutical products that are a recombinant humanized monoclonal antibody. It became the first angiogenesis inhibitor to be clinically used in 2004. Its development was majorly based on the discovery of the human vascular endothelial growth factor (VEGF). This is a protein that stimulated the growth of a blood vessel during a study done by Napoleone Ferrara, a Genentech scientist. He also successfully demonstrated that VEGF inhibits tumor growth in mice.

In countries such as the UK, the national health care system has restricted the drug based on cost-benefit calculations. The National Institute for Health and Care excellence took the stance that NHS should not fund the drug as it is available for sale at nearly £21,000 per patient. Also, it has minimal effects on patients. The Scottish Medicines Consortium also recommended against NHS funding in 2006 because of high costs. The drug was given a specialty drug status in 2014. It can be purchased from selected outlets. As per IMS, several hospitals charge £7000 more for this drug in comparison to its actual price. Hence, many hospitals are no longer eligible for the discounts that they were getting on the average wholesale price of this drug in several parts of the world. This is the reason why the manufacturers are interested in dealing with just reliable and licensed distributors for this drug. All the trade activities of Bevacizumab suppliers are being monitored by the authorities.

If you are a distributor eager to connect with reliable Bevacizumab drug manufacturers, then you can consider registering on the reliable online pharma market, Pipelinepharma. This platform offers you all the assistance that you require in cracking a pharma deal. The platform is convenient to use. All the manufacturers listed have been verified before being allowed to trade over the platform.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Sodium Alginate offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these pharmaceutical substance manufacturers and suppliers that you are looking for. These also enable you to check the dossier status of this medicine, and the GMP approvals of the different variants of this medicine. Also, each manufacturer or supplier product description contains essential information about this medicine including clinical data, stability zones, countries where it is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or distributors you can enter into deals or negotiations over Sodium Alginate offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that Sodium Alginate manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen these manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.